Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models
Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of monoamine-oxidase-B…Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)
Objective: To identify, characterize and treat dyskinesias and off time in a patient with PD via the use of gamma and beta peak LFP using…Laryngeal Electromyography Findings in patients with Multiple System Atrophy
Objective: to systematically evaluate laryngeal electromyography findings, correlate them to laryngeal movement disorders assessed by a systematic task-protocol performed during FEES and clinical laryngeal symptoms.…Unusual Progressive Supranuclear Palsy: a case report
Objective: Introduction: Progressive supranuclear palsy (PSP) is a rare brain condition. It is predominantly a sporadic disease that occurs between 45 and 75 years of…Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome
Objective: To measure bilateral in vivo and postmortem tau pathology in a well-characterized patient presenting with corticobasal syndrome (CBS) due to underlying neocortical stage Lewy…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 132
- Next Page »